With the acquisition of the French company KaLy-Cell SAS (KaLy-Cell), GBA Group expands its European pharmaceutical network. This is an important milestone for the GBA Group to offer a comprehensive service portfolio for national and international customers along the development phases of new safe medicines as well as chemicals for cosmetic and crop protection applications.
KaLy-Cell SAS was founded in 2003 as a spin-off of the French University of Bourgogne Franche-Comté. The company, now based in Plobsheim, provides contract research services using hepatocytes from different species to optimize the discovery, development and approval of medicines, food additives and agrochemicals. KaLy-Cell thus provides a significant contribution to relevant safety studies and enjoys an excellent reputation in the industry through its renowned customer base.
Dr. Sabine Gorynia, Global Head Pharma EVP: "KaLy-Cell is an excellent addition to our preclinical portfolio in the highly relevant in vitro field. With this acquisition, we are not only responding to a critical demand in the market, but also strengthening our team with excellent scientists. I am very much looking forward to the integration and successful collaboration."
"We are very proud to be part of the GBA Group," said Prof. Dr. Lysiane Richert, CSO KaLy-Cell. "Our common goal is to be able to offer an expanded service portfolio in the context of in vitro metabolic and safety analysis, especially in view of the current increasing demand for Integrated Approaches to Testing and Assessment (IATA) in safety studies and clarification of mechanisms of action."
With over 500 employees in Germany, Austria and France, GBA Group Pharma is one of the largest and most experienced service providers for pharmaceuticals and biotechnology in Europe. GBA Group Pharma is active in the entire supply and testing chain from medicine development to distribution. Preclinical and clinical services are just as much a part of this as, for example, analytical and QP services or central laboratory services.
KaLy-Cell SAS was founded in 2003 as a spin-off of the French University of Bourgogne Franche-Comté. The company, now based in Plobsheim, provides contract research services using hepatocytes from different species to optimize the discovery, development and approval of medicines, food additives and agrochemicals. KaLy-Cell thus provides a significant contribution to relevant safety studies and enjoys an excellent reputation in the industry through its renowned customer base.
Dr. Sabine Gorynia, Global Head Pharma EVP: "KaLy-Cell is an excellent addition to our preclinical portfolio in the highly relevant in vitro field. With this acquisition, we are not only responding to a critical demand in the market, but also strengthening our team with excellent scientists. I am very much looking forward to the integration and successful collaboration."
"We are very proud to be part of the GBA Group," said Prof. Dr. Lysiane Richert, CSO KaLy-Cell. "Our common goal is to be able to offer an expanded service portfolio in the context of in vitro metabolic and safety analysis, especially in view of the current increasing demand for Integrated Approaches to Testing and Assessment (IATA) in safety studies and clarification of mechanisms of action."
With over 500 employees in Germany, Austria and France, GBA Group Pharma is one of the largest and most experienced service providers for pharmaceuticals and biotechnology in Europe. GBA Group Pharma is active in the entire supply and testing chain from medicine development to distribution. Preclinical and clinical services are just as much a part of this as, for example, analytical and QP services or central laboratory services.
